Knight TherapeuticsFRA:04K +0.83%73 EV-to-FCF is 13.15 as of Jul. 07, 2026, which is 18% below its 10-year median of 16.07. GuruFocus rates FRA:04K with a GF Score™ of 73/100 and a GF Value™ of €5.27. The stock has 6 warning signs investors should review. Among 563 Drug Manufacturers companies, Knight Therapeutics ranks better than 68.38% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Knight Therapeutics's Enterprise Value is €561.3 Mil.
Knight Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €42.7 Mil. Therefore, Knight Therapeutics's EV-to-FCF for today is 13.15.
The historical rank and industry rank for Knight Therapeutics's EV-to-FCF or its related term are showing as below:
FRA:04K'
s EV-to-FCF Range Over the Past 10 Years
Min: -412.4 Med: 16.07 Max: 504.07
Current: 13.13
During the past 13 years, the highest EV-to-FCF of Knight Therapeutics was 504.07. The lowest was -412.40. And the median was 16.07.
FRA:04K's EV-to-FCF is ranked better than 68.38% of 563
companies
in the Drug Manufacturers industry
Industry Median: 20.85
vs FRA:04K: 13.13
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Knight Therapeutics's PE Ratio (TTM) for today is calculated as:
Knight Therapeutics's share price for today is €6.10.
Knight Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.031.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Knight Therapeutics EV-to-FCF Related Terms
Knight Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Knight Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Knight Therapeutics EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Knight Therapeutics's EV-to-FCF falls into.
Knight Therapeutics's current Enterprise Value is €561.3 Mil.
Knight Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €42.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Knight Therapeutics (FRA:04K) has a EV-to-FCF of 13.15 as of Jul. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Knight Therapeutics and its competitors. This is 18% below median its historical median of 16.07. According to the industry distribution chart, Knight Therapeutics ranks #178 out of 563 companies in the Drug Manufacturers industry, placing it in the top 31.6%.
Is Knight Therapeutics' EV-to-FCF too high?
Knight Therapeutics' current EV-to-FCF of 13.15 is 18% below median its 10-year median of 16.07. The Drug Manufacturers industry median EV-to-FCF is 20.85. Knight Therapeutics' value of 13.15 is 36.9% below this industry median. Based on the distribution chart, Knight Therapeutics ranks #178 out of 563 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Knight Therapeutics has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Knight Therapeutics ranks #178 out of 563 companies for EV-to-FCF. This puts Knight Therapeutics in the upper half of its industry. The industry median EV-to-FCF is 20.85. Knight Therapeutics' value of 13.15 is 36.9% below this benchmark. While the company's 10-year median is 16.07 vs. the industry median of 20.85, Knight Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.85, based on 563 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Knight Therapeutics's current EV-to-FCF of 13.15 is 36.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Knight Therapeutics and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Knight Therapeutics's current EV-to-FCF is 13.15, which is 18% below median its own 10-year median of 16.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Knight Therapeutics (FRA:04K) has a current EV-to-FCF of 13.15. The stock's GF Value™ is €5.27, compared to a current price of €6.10 — trading 15.7% above its estimated fair value. The current EV-to-FCF is 13.15, which is 18% below median its 10-year median of 16.07 and 36.9% below the Drug Manufacturers industry median of 20.85. Knight Therapeutics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Knight Therapeutics (FRA:04K), the current EV-to-FCF is 13.15 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Knight Therapeutics (FRA:04K) Overvalued in 2026?
Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued.
The current stock price of €6.10 is trading 15.7% above its estimated GF Value™ of €5.27.
Key valuation signals for FRA:04K:
EV-to-FCF: 13.15 (18% below median its 10-year median of 16.07)
GF Value™: €5.27 vs. price of €6.10 (15.7% above fair value)
Industry Position: 36.9% below the Drug Manufacturers median (#178 of 563)
No single metric tells the full story. See the FRA:04K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
73GF Score
Get the complete analysis for FRA:04K
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:04K has been successfully added to your 
